标题
Novel Human Bispecific Aptamer–Antibody Conjugates for Efficient Cancer Cell Killing
作者
关键词
-
出版物
Cancers
Volume 11, Issue 9, Pages 1268
出版商
MDPI AG
发表日期
2019-08-29
DOI
10.3390/cancers11091268
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications
- (2018) Simona Camorani et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC
- (2018) Xue Li et al. CANCER LETTERS
- Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice
- (2018) Eva-Maria Rom-Jurek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies
- (2018) Emanuele Sasso et al. mAbs
- Targeting tumour microenvironment by tyrosine kinase inhibitor
- (2018) Hor-Yue Tan et al. Molecular Cancer
- Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
- (2018) Claudia De Lorenzo et al. OncoTargets and Therapy
- Current Advances in Aptamers for Cancer Diagnosis and Therapy
- (2018) Shin-ichiro Hori et al. Cancers
- T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells
- (2018) Gennaro Riccio et al. JOURNAL OF IMMUNOTHERAPY
- Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma
- (2017) Rutveej Patel et al. Expert Opinion on Drug Metabolism & Toxicology
- Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells
- (2017) Xun Wang et al. IMMUNOLOGY LETTERS
- Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody
- (2017) Gennaro Riccio et al. JOURNAL OF IMMUNOTHERAPY
- Three Drugs Approved for Urothelial Carcinoma by FDA
- (2017) Cancer Discovery
- EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
- (2017) Koung Jin Suh et al. Oncotarget
- Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers
- (2017) Simona Camorani et al. Scientific Reports
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors
- (2016) Nicola Maurea et al. Journal of Cardiovascular Medicine
- An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies
- (2016) Kyun Heo et al. JOURNAL OF CONTROLLED RELEASE
- Antibodies to watch in 2017
- (2016) Janice M. Reichert mAbs
- Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
- (2016) Gennaro Riccio et al. Human Vaccines & Immunotherapeutics
- Self-Assembled Hybrid Aptamer-Fc Conjugates for Targeted Delivery: A Modular Chemoenzymatic Approach
- (2015) Stephan Dickgiesser et al. ACS Chemical Biology
- Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology
- (2015) Dan Shu et al. ACS Nano
- Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1
- (2015) Amer Assal et al. Immunotherapy
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells
- (2015) Simona Camorani et al. Oncotarget
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
- (2015) Aitziber Buqué et al. OncoImmunology
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
- (2014) K. Azuma et al. ANNALS OF ONCOLOGY
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling
- (2014) Lei Zheng et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Inhibition of Receptor Signaling and of Glioblastoma-derived Tumor Growth by a Novel PDGFRβ Aptamer
- (2014) Simona Camorani et al. MOLECULAR THERAPY
- PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2014) H. Wimberly et al. Cancer Immunology Research
- Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer
- (2014) Jessica M Baron et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer
- (2013) C. Chung et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Novel antibodies targeting immune regulatory checkpoints for cancer therapy
- (2013) Chern Siang Lee et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of a human compact anti-ErbB2 antibody on gastric cancer
- (2013) Carmine Fedele et al. Gastric Cancer
- Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1-Mediated Immune Suppression
- (2013) S. T. Haile et al. JOURNAL OF IMMUNOLOGY
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Suppression of FUT1 attenuates cell proliferation in the HER2-overexpressing cancer cell line NCI-N87
- (2012) SADAYUKI KAWAI et al. ONCOLOGY REPORTS
- Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors
- (2011) Carmine Fedele et al. BREAST CANCER RESEARCH AND TREATMENT
- A novel ErbB2 epitope targeted by human antitumor immunoagents
- (2011) Fulvia Troise et al. FEBS Journal
- A Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell Death
- (2011) Carla Lucia Esposito et al. PLoS One
- Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours
- (2010) T Gelardi et al. BRITISH JOURNAL OF CANCER
- Aptamers as therapeutics
- (2010) Anthony D. Keefe et al. NATURE REVIEWS DRUG DISCOVERY
- Therapeutic antibodies: successes, limitations and hopes for the future
- (2009) Patrick Chames et al. BRITISH JOURNAL OF PHARMACOLOGY
- Androgen Receptor Controls EGFR and ERBB2 Gene Expression at Different Levels in Prostate Cancer Cell Lines
- (2009) J.-C. Pignon et al. CANCER RESEARCH
- Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
- (2009) K. S. Peggs et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents
- (2009) Gennaro Riccio et al. FASEB JOURNAL
- Human anti-ErbB2 immunoagents - immunoRNases and compact antibodies
- (2009) Claudia De Lorenzo et al. FEBS Journal
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More